Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JT Licenses Hyperlipidemia Drug to Roche
November 1, 2004
- PRESS SEMINAR
November 1, 2004
- Eisai Machinery Starts Operations on Oct. 1
November 1, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 1, 2004
- JPMA Conducts Survey on Compliance with Promotion Code
November 1, 2004
- Fuji Chemical Industry Develops New Filler for Orally Disintegrating Tablets
November 1, 2004
- Novartis' Zometa Approved for Hypercalcemia due to Malignant Tumors
November 1, 2004
- Standard Chemotherapy for NSCLC to Be Specified in GLs
November 1, 2004
- Tsumura Sets Standards for Pesticide Residues in Crude Drugs
November 1, 2004
- REGULATORY NEWS IN BRIEF
November 1, 2004
- JPMA, FPMAJ Call For Preferential Tax System for Orphan Drugs
November 1, 2004
- 35 Healthcare-related Bodies Rally against "Mixed Medical Care"
November 1, 2004
- Wishing to Clarify Real Role of FPMAJ: Chairman Takeda
November 1, 2004
- Korosho Study Group Prepares Package Inserts for Patients
November 1, 2004
- DIAGNOSTIC NEWS IN BRIEF
November 1, 2004
- Korosho Study Group on Vaccination Holds 1st Meeting
November 1, 2004
- BULLETIN
November 1, 2004
- No Consensus on "Method Patents" in Medical Field
November 1, 2004
- Alesion Dry Syrup to Be Approved
November 1, 2004
- MEDICAL DEVICE NEWS IN BRIEF
November 1, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…